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NeuroprotectionDiminished lysosomal function can lead to abnormal cellular accumulation of speciﬁc proteins, including α-
synuclein, contributing to disease pathogenesis of vulnerable neurons in Parkinson's disease (PD) and related
α-synucleinopathies. GBA1 encodes for the lysosomal hydrolase glucocerebrosidase (GCase), and mutations in
GBA1 are a prominent genetic risk factor for PD. Previous studies showed that in sporadic PD, and in normal
aging, GCase brain activity is reduced and levels of corresponding glycolipid substrates are increased. The present
study testedwhether increasing GCase through AAV-GBA1 intra-cerebral gene delivery in two PD rodentmodels
would reduce the accumulation of α-synuclein and protect midbrain dopamine neurons from α-synuclein-
mediated neuronal damage. In the ﬁrst model, transgenicmice overexpressingwildtypeα-synuclein throughout
the brain (ASO mice) were used, and in the second model, a rat model of selective dopamine neuron degenera-
tionwas induced by AAV-A53Tmutantα-synuclein. In ASOmice, intra-cerebral AAV-GBA1 injections into sever-
al brain regions increasedGCase activity and reduced the accumulation ofα-synuclein in the substantia nigra and
striatum. In rats, co-injection of AAV-GBA1 with AAV-A53T α-synuclein into the substantia nigra prevented α-
synuclein-mediated degeneration of nigrostriatal dopamine neurons by 6months. These neuroprotective effects
were associated with altered protein expression of markers of autophagy. These experiments demonstrate, for
the ﬁrst time, the neuroprotective effects of increasing GCase against dopaminergic neuron degeneration, and
support the development of therapeutics targetingGCase or other lysosomal genes to improve neuronal handling
of α-synuclein.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
GBA1 encodes for the lysosomal hydrolase glucocerebrosidase
(GCase) and clinical and neuropathological evidence links GBA1 to PD
and related α-synucleinopathies (Eblan et al., 2006; Gegg et al., 2012;
Neumann et al., 2009; Rocha et al., 2015a; Sidransky et al., 2009;
Velayati et al., 2010). Approximately 4–7% of PD-patients are carriers
of a heterozygous GBA1 mutation, resulting in 30–40% diminished
GCase activity (Neumann et al., 2009; Sidransky et al., 2009). PD-
patients who harbor a GBA1 mutation that results in a reduction in
GCase activity usually develop more severe symptoms, are oftenrch Institute, McLean Hospital/
78, USA.
allett),
ect.com).
. This is an open access article underdiagnosed earlier and are associated with increased α-synuclein accu-
mulation then non-GBA1 mutation carrying PD-patients (Bras et al.,
2009; Murphy et al., 2014; Sidransky et al., 2009). As a consequence of
this genetic link, attention is being focused on uncovering the relation-
ship betweenGCase and sporadic PD,which should give insight into the
pathophysiology of the disease. Several studies, including our own, have
demonstrated a reduction of GCase activity in the brain of sporadic PD
patients (Gegg et al., 2012; Rocha et al., 2015a), and our data also
showed that reduced GCase activity is paralleled by increased levels of
the glycolipid substrate glucosylsphingosine. Moreover, we have
shown that there is a progressive age-dependent reduction in GCase ac-
tivity in healthy subjects in brain regions most affected in PD (Rocha
et al., 2015a).
Diminished GCase activity can promote α-synuclein aggregation
in vitro and in vivo (Mazzulli et al., 2011; Sardi et al., 2011) and systemic
administration of the GCase inhibitor, conduritol β epoxide, CBE, in-
duces α-synuclein aggregation in the substantia nigra of wildtype
mice (Rocha et al., 2015b). Overexpression of GBA1 has been shown tothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
496 E.M. Rocha et al. / Neurobiology of Disease 82 (2015) 495–503reduce α-synucleinopathy (Sardi et al., 2011; Sardi et al., 2013) and
therefore would presumably protect vulnerable nigral dopamine neu-
rons from PD-like degeneration. To investigate the therapeutic
potential of GCase for PD, we overexpressed GBA1 by means of adeno-
associated virus (AAV) in two rodent models of α-synucleinopathy. To
determine whether overexpression of GBA1 can reduce α-synuclein
inclusions in the striatum and substantia nigra we used a transgenic
mouse model causing widespread α-synucleinopathy (Fleming et al.,
2004; Hallett et al., 2012). Second, to measure the direct neuroprotec-
tive effects of increasedGCase activity onmidbrain dopamine (DA) neu-
rons, we utilized a well-established rat model of α-synucleinopathy
that causes progressive loss of DA neurons (Chung et al., 2009).
2. Materials and methods
2.1. Animals
Transgenic mice that overexpress human wildtype α-synuclein
(ASO) on the Thy-1 promoter (Rockenstein et al., 2002; Fleming et al.,
2004; Hallett et al., 2012) were bred in house. Male mice were used
for experimental procedures. Female Sprague–Dawley rats approxi-
mately 250–300 g (Charles River Laboratories) were used for the neuro-
protection experiment. Animals were housed in standard conditions in
a dark/light cycle of 12 h, with ad libitum access to food and water. All
animal procedures were performed in accordance with National Insti-
tute of Health guidelines andwere approved by the Institutional Animal
Care and Use Committee (IACUC) at McLean Hospital, Harvard Medical
School.
Two- to three-month old ASO mice were randomly selected for one
of two treatment groups: either AAV2/5-synapsin GFP (n = 10) or
AAV2/5-synapsin GBA1 (n = 13). AAV viruses containing each of the
transgenes were delivered to mice by intra-cerebral injections and
mice were returned to their homecages after the procedure. A cohort
of these mice was euthanized 3-months post-gene delivery for bio-
chemical analysis (AAV2/5-synapsin GFP, n = 6; AAV2/5-synapsin
GBA1, n = 8), and the remaining mice were euthanized 8-months
post-gene delivery for histological analysis (AAV2/5-synapsin GFP,
n= 4; AAV2/5-synapsin GBA1, n= 5).
Female rats (250–300 g) were randomly selected for one of three
treatment groups: either AAV2/2-synapsin GFP (n = 8) or AAV2/2-
synapsin A53T α-synuclein + AAV2/2-synapsin GFP (n = 14) or
AAV2/2-synapsin A53T α-synuclein +AAV2/2-synapsin GBA1 (n =
15). AAV viruses containing each of the transgenes were delivered to
rats by intra-cerebral injections and rats were returned to their
homecages after the procedure. A cohort of these rats was euthanized
8-weeks post-gene delivery for biochemical analysis (AAV2/2-synapsin
GFP, n = 4; AAV2/2-synapsin A53T α-synuclein + AAV2/2-synapsin
GFP, n = 5; AAV2/2-synapsin A53T α-synuclein + AAV2/2-synapsin
GBA1, n= 5), and the remaining rats were euthanized 24-weeks post-
gene delivery for histological analysis (AAV2/2-synapsin GFP, n = 4;
AAV2/2-synapsin A53T α-synuclein + AAV2/2-synapsin GFP, n = 9;
AAV2/2-synapsin A53Tα-synuclein+ AAV2/2-synapsin GBA1, n=10).
2.2. Recombinant AAV preparation
For theWT and ASOmouse surgeries, AAV2/5-GBA1 vector contain-
ing the coding sequence for the human GBA1 gene and under the
synapsin promoter was injected into various brain regions. The ﬁnal ti-
ters for the vectors encoding human GBA1 and GFP were 2.0 × 1012 ge-
nome copies/mL. For the rat surgeries, AAV2/2-GBA1 and AAV2/2-
A53T-α-synuclein vectors containing the coding sequences for the
human GBA1 gene and for the human α-synuclein gene, respectively,
were co-injected into the substantia nigra in the same injectate, at a
ﬁnal titer of 2.0 × 1012 genome copies/mL. Vectors were under the con-
trol of the synapsin promoter. The GBA1 plasmid was obtained from
Origene, and Virovek completed virus production. Details on the virusproduction for mutant A53T-α-synuclein have previously been
described (Chung et al., 2009).
2.3. Stereotaxic surgeries
Stereotaxic coordinates forWT and ASOmice surgeries were obtain-
ed using a mouse atlas by Paxinos and Watson (1986). Before surgery,
mice were anesthetized using Nembutol sodium (50 mg/kg). The mice
were placed in a stereotaxic frame (Stoelting), where a 10 μL Hamilton
syringe and 31 gauge needle were used as a delivery system. Two injec-
tion sites into the striatum were achieved using the following coordi-
nates: anteroposterior (AP): +1.4, +0.1 mm; mediolateral (ML):
−1.5,−2.0 mm; and dorsoventral (DV):−2.5, −3.5 and−2.2 mm,
all relative to bregma. Two injections into the hippocampus were
achieved using the following coordinates: AP: −2.0, −3.2 mm; ML:
−1.5,−3mm; andDV:−1.5,−3.2mm, all relative to bregma. A single
injection into the substantia nigra was achieved using the following co-
ordinates: AP:−3.2 mm, ML:−1.3mm, and DV:−1.4 mm, all relative
to bregma. Two microliters of either AAV-GFP or AAV-GBA1 was
injected unilateral at a rate of 1 μL/min using a microinfusion pump
(Stoelting), with a wait time of 2 min between injections.
Stereotaxic coordinates for rat surgeries were obtained using a rat
atlas by Paxinos andWatson (1986). Before surgery, rats were anesthe-
tized using xylazine and ketamine (3 mg/kg and 60 mg/kg, respective-
ly). The mice were placed in a stereotaxic frame (Kopf), where a 10 μL
Hamilton syringe and 31 gauge needle were used as a delivery system.
Two injections into the substantia nigrawere achieved using the follow-
ing coordinates: AP:−4.8,−5.5 mm; ML:−2.1, −1.9 mm; and DV:
−7.1,−7.0 mm, all relative to bregma. Toothbar was set at−3.3 mm.
Two microliters of AAV-GFP, AAV-A53T α-synuclein + AAV-GFP, or
A53T α-synuclein + AAV-GBA1 was injected unilateral at a rate of 0.5
μL/min using a microinfusion pump (Stoelting) with a wait time of
5 min between injections.
2.4. Immunohistochemistry and antibodies
Animals were terminally anesthetized with sodium pentobarbital
and perfused transcardially with heparinized saline (0.1% heparin in
0.9% saline) followed by 4% paraformaldehyde in phosphate buffer.
Brains were removed and post-ﬁxed in 4% paraformaldehyde for
4 hours (h) before placing them 30% sucrose. Forty-micrometer thick
coronal sections were then collected, using a sledge microtome and
stored in antifreeze at−20 °C until use. Free-ﬂoating mouse brain sec-
tions were collected in a 1 in 6 series and free-ﬂoating rat sections were
collected in a 1 in 12 series.
The primary antibodies used included chicken anti-GFP (Aves,
1:1000), mouse anti-GBA (Abcam, 1:1000), rabbit anti-LC3 (Millipore,
1:500), mouse anti-α-synuclein (BD Transduction, 1:1000), rabbit
anti-LAMP-2A (Invitrogen, 1:200), rabbit anti-p62 (Cell Signaling,
1:200), chicken anti-GAPDH (Millipore, 1:5000), anti-rabbit TH
(Pelfreeze, 1:300), and anti-mouseNeuN (Millipore, 1:1000).Horseradish
peroxidase-conjugated goat anti-chicken, anti-rabbit, and anti-mouse (all
Jackson ImmunoResearch, 1:10,000)were used forWestern blot analysis.
Donkey biotin-conjugated anti-rabbit (Jackson ImmunoResearch,
1:200) was used for brightﬁeld microscopy.
Transgene expression was assessed at 24-weeks post-gene delivery
in every rat using immunoﬂuorescence based histology; co-stains were
carried out using a 1 in 12 series of sections. Brain sections were rinsed
3× for 5min using PBS to remove antifreeze andwere blockedwith 10%
normal serumusing PBS-0.3% triton-X for 1 h at room temperature. Sec-
tions were incubated with primary antibodies at 4 °C overnight using
blocking solution. Sections were then washed 3× using PBS and incu-
batedwith secondary antibodies diluted in PBS for 1 h at room temper-
ature. Sections were submersed in Hoechst (1 mg/200 mL) for 4–
5 min and washed 3× using PBS. Tissue sections were mounted using
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confocal microscope using Zen 2009 software.
2.5. Glucocerebrosidase activity
GCase activity was measured in the striatum (n= 5–6), hippocam-
pus (n = 3–6) and substantia nigra (n = 6–8) of mice treated with
either AAV-GFP or AAV-GBA1 3-months post-gene delivery and in rats
treated with either AAV-GFP, AAV-α-synuclein + AAV-GFP or AAV-α-
synuclein + AAV-GBA 8 weeks post-gene delivery, using a previously
described protocol with some modiﬁcations (Sellos-Moura et al.,
2011); brain tissues (~5 mg) were homogenized in 300 μL of water.
Samples were diluted in a 2 mg/mL BSA, citric acid sodium phosphate
buffer (pH 5). Ten microliter of sample was added to 75 μL of 10 mM
4-methylumbelliferyl-β-D-glucopyranoside (Sigma, USA) substrate.
After incubation with the substrate for 60 min at 37 °C, the reaction
was terminated using 200 μL of stop solution (0.3 M glycine/0.2M sodi-
um carbonate, pH 10.7). Plates were read (Ex 360/Em 460) in a Molec-
ular Devices SPECTRAmax plate reader using Softmax Pro software.
Enzymatic activity was assessed from a 4-methylumbelliferyl (Sigma,
USA) standard curve and normalized to protein content in each sample
as determined using a BCA kit (Thermo Scientiﬁc Pierce, USA).
2.6. Staining and quantiﬁcation of insoluble α-synuclein aggregates
To visualize insoluble α-synuclein aggregates, free-ﬂoating tissue
sections were collected using 1 in 6 series from ASO mice injected
with AAV2/5-synapsin GFP (n= 4) or AAV2/5-synapsin GBA1 (n= 5)
and pre-mounted on gelatin-coated slides. Tissue sections were incu-
bated with proteinase-K solution (10 μg/mL; Promega) for 20–30 min
at 37 °C. Endogenous peroxidases were quenched in 3% hydrogen per-
oxide for 7 min and placed in a blocking solution (Vectashield MOM
kit) for 1 h at room temperature. Tissue sections were incubated with
anti-α-synuclein (1:1000; BD Transduction) overnight at 4 °C using pri-
mary antibody diluent (Vectashield MOM kit). Sections were incubated
with anti-mouse biotinylated secondary antibody (1:200) for 1 h at
room temperature and visualized using a standard peroxidase-based
method (Vectastain Elite, ABC kit, Vector Laboratories, Burlingame CA,
USA) and the chromogen, 3,3′-diaminobenzadine (Sigma).
Semi-quantitative scores for the number of insoluble α-synuclein
aggregates were quantiﬁed using the threshold function in Image J soft-
ware (Version1.46r). Photomicrographswere taken using25× and 60×
magniﬁcation in deﬁned regions of the substantia nigra and striatum,
respectively. Photomicrographs were duplicated and converted to
grayscale. The threshold of the grayscale was adjusted until only the
dark α-synuclein inclusions remained visible on the image, removing
all background staining. The image was then inverted and the number
of α-synuclein inclusions was quantiﬁed for each image using the ana-
lyze particles function. Parameters of this function were set to measure
particles at the size (pixels2) of 1-inﬁnity and the circularity of 0–1.
2.7. Stereology
To quantify the number of surviving dopamine neurons in the
substantia nigra pars compacta, every 12th section of the substantia
nigra was collected from rats injected with AAV2/2-synapsin GFP
(n = 4) or AAV2/2-synapsin A53T α-synuclein + AAV2/2-synapsin
GFP (n = 9) or AAV2/2-synapsin A53T α-synuclein + AAV2/2-
synapsin GBA1 (n = 10). Free-ﬂoating tissue sections were rinsed in
PBS before endogenous peroxidases were quenched in 3% hydrogen
peroxide for 7 min. After rinsing, the sections were incubated in 0.1%
Triton X-100 in PBS containing 10% normal serum. Tissue sections
were then incubated sequentiallywith anti-TH and anti-NeuN antibodies
overnight at 4 °C. After each primary antibody, sections were washed
in PBS, incubated in biotinylated secondary antibody (1:200), and
visualized using a standard peroxidase-based method (Vectastain Elite,ABC kit, Vector Laboratories, Burlingame CA, USA) and the chromogen,
3,3′-diaminobenzadine (Sigma). An investigator blinded to animal treat-
ment groups counted the number of neurons colabeled for TH and NeuN
using nonbiased stereology using the optical fractionatormethod at 20 ×
magniﬁcation from MBF Bioscience (Stereoinvestigator 7) and the
following parameters: a 150 μm × 150 μm counting frame and
200 × 200 μm grid. One-way ANOVA statistical analyses were per-
formed followed by Bonferroni post-hoc test.
2.8. Western blotting
Transgene expression and changes in autophagy were measured
in the substantia nigra, striatum, and hippocampus by Western blot
in mice treated with either AAV2/5-synapsin GFP (n = 3–8) or
AAV2/5-synapsin GBA1 (n = 5–6) 3-months post-gene delivery
and in the substantia nigra and striatum of rats treated with either
AAV2/2-synapsinGFP (n=4) orAAV2/2-synapsinA53Tα-synuclein+
AAV2/2-synapsin GFP (n = 5) or AAV2/2-synapsin A53T α-
synuclein + AAV2/2-synapsin GBA1 (n=5) 8-weeks post-gene de-
livery. Mice and rats were terminally anesthetized and perfused
transcardially with heparinized saline (0.1% heparin in 0.9% saline)
and brains were cut using a tissue chopper at 750 μm and 1 mm, re-
spectively. Tissue samples were homogenized ice cold buffer con-
taining: 300 mM sucrose in TE buffer (Bio-Rad). Phosphatase
inhibitors I and II (1:100) and proteinase inhibitors (1:100) (Thermo
Halt proteinase inhibitor single use cocktail) and EDTA were then
added. Tissues were homogenized for 15 s and sonicated in with three
short pulses. Twenty micrograms of protein were loaded into the Crite-
rion precast 4–12.5% SDS polyacrylamide gel system (Bio-Rad). The
proteins were then transferred to PVDF membranes. Membranes were
washed in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) and
blocked in 5% milk for 1 h at room temperature prior to incubation
with desired primary antibodies overnight at 4 °C. The membranes
were probed with the following the desired primary antibody. After
washing in TBS-T, HRP-conjugated secondary antibodies were then ap-
plied for 1 h at room temperature. The blots were treated with ECL-Plus
(Amersham Biosciences) and exposed using ChemiDoc™ XRS with
image Lab™ software. Optical density analysis (NIH image) was used
to determine the relative abundance of each protein of interest.
2.9. Statistical analysis
All analyses were conducted using GraphPad Prism (Version 5.0)
(GraphPad Software, Inc). Statistical signiﬁcance was determined at
the alpha level of 0.05.
3. Results
3.1. Overexpression of GCase reduced the number and size of insoluble α-
synuclein aggregates in mice overexpressing human wildtype α-synuclein
The mechanism(s) by which α-synuclein oligomeric species in-
crease neuronal vulnerability are not fully understood, but likely involve
disruption of proteostasis (Kayed et al., 2004;Manning-Bog et al., 2009).
Therefore, we wanted to address whether overexpression of GCase ac-
tivity could decrease levels of the oligomeric and aggregated forms of
α-synuclein. Unilateral injections of either AAV-GBA1 or AAV-GFP con-
trol were delivered to 2-3-month old ASO mice in the striatum,
substantia nigra and hippocampus (Fig. 1A). GCase activity increased
in the striatum (T1,7 = 2.602, p b 0.05), substantia nigra (T1,7 = 2.496,
p b 0.05), and hippocampus (T1,7 = 4.033, p b 0.05) 3 months post-
AAV injection (Fig. 1B). This corresponded to an increase in the protein
levels of GCase in the substantia nigra (T1,7 = 4.033, p b 0.05), striatum
(T1,7 = 2.60, p b 0.05), and hippocampus (T1,7 = 2.496, p b 0.05) (Fig.
1C).
Fig. 1. AAV-GBA1 gene therapy induces an increase in GBA protein levels and GCase activity. Two- to three-month old ASO mice received unilateral injections into the substantia nigra,
striatum and hippocampus of either AAV-GFP control or AAV-GBA1 (A). Overexpression of AAV-GBA1 caused an increase in GCase activity in the substantia nigra, striatum, and hippo-
campus in comparison to AAV-GFP control mice (B). Western blots were performed using total lysate (20 μg) from the substantia nigra, striatum and hippocampus 3-months post-
AAV injection to verify transgeneoverexpression (C).N=5animals per group. Data are analyzedusing anunpaired two-tailed T-test, *p b 0.05, graphs expressed asmean±SEM.Western
blots show two representative samples from each group.
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synuclein pathology (Fleming et al., 2004; Hallett et al., 2012). Overex-
pression of GBA1 in ASO mice increased LC3-II levels in the substantia
nigra (T2,4= 3.80, p b 0.05) and striatum (T2,7= 2.65, p b 0.05), in com-
parison to AAV-GFP injected ASO mice (Fig. 2A). This increase in LC3-II
coincided with a 40% reduction in high molecular weight (HMW) α-
synuclein oligomeric species in the SN (T2,6 = 3.18, p b 0.05) and in
the striatum (T2,8 = 4.67, p b 0.05) in comparison to AAV-GFP injected
mice (Fig. 2B). In contrast, levels of LC3-II and HMW α-synuclein
remained unchanged in the hippocampus in AAV-GBA1 treated
ASO mice in comparison to ASO mice treated with AAV-GFP (Fig. 2A
and B).
In addition to reducing soluble α-synuclein oligomeric intermedi-
ates, wewanted to assess whether GBA1 overexpression could decrease
the number of insoluble α-synuclein aggregates when ASO mice were
10–11 months of age (corresponding to 8 months post-AAV injection),
a timepoint when α-synuclein pathology is extensive (Chesselet et al.,
2012). Transgene expression of GBA1 was ﬁrst conﬁrmed at 8 months
post-gene delivery in the substantia nigra (Fig. 3A), striatum (Fig. 3D)
and hippocampus (data not shown) by immunoﬂuorescence. We used
awell-established histology protocol to visualize aggregates of insoluble
α-synuclein (Fernagut et al., 2007). The number of proteinase-K resis-
tant insoluble α-synuclein aggregates was quantiﬁed and normalized
to the contra-lateral (non-injected) side. Overexpression of GBA1
reduced the number and size of the proteinase-K resistant insoluble
α-synuclein aggregates in the substantia nigra (T2,7 = 2.733, p b 0.05)
and striatum (T2,8 = 2.863, p b 0.05), 8-months post-gene delivery. To
determine if AAV-GBA1 prevented the accumulation of α-synuclein
aggregates of different sizes or was able to prevent accumulation of
aggregates of a speciﬁed size, we arbitrarily grouped the α-synuclein
aggregates into groups and used the same protocol to quantify the
reduction in the number of aggregates. AAV-GBA1 caused a reduction
in the number of α-synuclein aggregates in the substantia nigra be-
tween 0 and 10 μm2 (T2,7 = 2.73, p b 0.05), 11–20 μm2 (T2,7 = 2.59,
p b 0.05), 21–50 μm2 (T2,7 = 2.61, p b 0.05) and N100 μm2 (T2,7 =
2.73, p b 0.05) compared to AAV-GFP injected littermate control ASO
mice (Fig. 3B–C). AAV-GBA1 also reduced the number of α-synuclein
aggregates in the striatum between 0 and 0.5 μm2 (T2,8 = 5.05, p b0.05), 0.6–1 μm2 (T2,8 = 4.34, p b 0.05), 2–5 μm2 (T2,8 = 2.85,
p b 0.05) and 6–10 μm2 (T2,7 = 5.06, p b 0.05) compared to AAV-GFP
injected littermate control ASO mice (Fig. 3E–F). Therefore, AAV-GBA1
prevented the accumulation of aggregates of all sizes except those
between 51 and 100 μm2. There was a trend towards a reduction in
number of aggregates between 51 and 100 μm2; however, due to the
variability this was statistically insigniﬁcant.3.2. Overexpression of GCase protects nigrostriatal dopaminergic neurons
from degeneration
The therapeutic potential of GBA1was tested using a ratmodel ofα-
synucleinopathy, which causes a 50% reduction in TH-positive neurons
and accumulation of α-synuclein inclusions, 24-weeks post-AAV
injection (Chung et al., 2009). This is in contrast to our ﬁrst model of
α-synucleinopathy, which exhibits a progressive and widespread accu-
mulation of insoluble α-synuclein but does not cause a loss of the
TH-positive dopamine neurons in the substantia nigra.
Naive rats received an intra-nigral injection of either (1) AAV-GFP
(control), (2) AAV-GFP + AAV-mutant A53T α-synuclein, or (3) AAV-
GBA1 + AAV-mutant A53T α-synuclein (Fig. 4A). AAV-GBA1 caused
an increase in GCase activity (F2,11 = 32.34, p b 0.05) in the substantia
nigra, 8-weeks post-AAV injection (Fig. 4B), which was paralleled by
an increase GCase protein levels (F2,11 = 9.994, p b 0.05) (Fig. 4C). At
24-weeks post-AAV injection, the transgene expressions of the viruses
remained elevated in the dopamine neurons of the substantia nigra
(Fig. 4D). Consistent with previous reports (Chung et al., 2009), we
found that intra-nigral administration of AAV-mutant A53T α-
synuclein caused a signiﬁcant (50%; F2,22 = 7.89, p b 0.05) decrease in
the number of dopamine neurons compared to control rats injected
with AAV-GFP (Fig. 5). Co-administration of AAV-GBA1 with AAV-
mutant A53Tα-synuclein preventedmutant A53Tα-synuclein induced
degeneration of the dopamine neurons of the substantia nigra pars
compacta and dopamine neuron number was comparable to that in
AAV-GFP injected control rats (Fig. 5). Therefore, this data demonstrates
that intra-nigral administration of AAV-GBA1 can rescue dopaminergic
neurons from A53T α-synuclein-induced degeneration.
Fig. 2. Intra-cerebral injection of AAV-GBA1 in ASO mice increases LC3-II and reduces
levels of high molecular weight (HMW) α-synuclein, 3-months post-gene therapy deliv-
ery. Gene delivery of AAV-GBA1 increased protein levels of LC3-II in the substantia nigra
and striatum in comparison to AAV-GFP control mice (A). In contrast, levels of LC3-II
remained unchanged in the hippocampus (A). AAV-GBA1 caused an increase in LC3-II,
which corresponded to a reduction in the number ofHMWα-synuclein oligomeric species
in the substantia nigra and striatum in comparison to AAV-GFP control mice (B). Consis-
tent with protein levels of LC3-II in the hippocampus, the number of HMW α-synuclein
oligomeric species remained unchanged in the hippocampus (B). N = 5 animals per
group. Data are analyzed using an unpaired two-tailed T-test, *p b 0.05, graphs expressed
as mean ± SEM. Western blots show two representative samples from each group.
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related proteins
To determine whether overexpression of GBA1 altered levels of pro-
teins associatedwith eithermacroautophagy and/or chaperonemediat-
ed autophagy (CMA), key proteins involved in both pathways were
explored at a pre-degenerative time point, 8-weeks post-AAV gene de-
livery. Speciﬁcally, Western blots were performed using total lysate
from the SN and the striatum of naive rats that received intra-nigral
injections of (1) AAV-GFP (control), (2) AAV-GFP + AAV-mutant
A53T α-synuclein or (3) AAV-GBA1 + AAV-mutant A53T α-synuclein.
At 8-weeks post-gene delivery, the lipidated form of LC3 (LC3-II)
remained unchanged in the substantia nigra (Fig. 6A). However, LC3-II
was signiﬁcantly decreased (F2,11 = 8.15, p b 0.05) in the striatum of
rats that received AAV-mutant A53Tα-synuclein, whichwas prevented
by gene delivery of GBA1 (Fig. 6D). The ubiquitin-like protein p62 was
decreased (F2,10 = 5.45, p b 0.05) in the substantia nigra of rats that re-
ceived an intra-nigral injection AAV-mutant A53T α-synuclein, which
was also prevented by the co-administration of AAV-GBA1 (Fig. 6B).
AAV-mutant A53T α-synuclein alone failed to induce a change in p62in the striatum of rats; however, when co-administered with AAV-
GBA1, p62was signiﬁcantly increased (F2,12= 5.98, p b 0.05) in the stri-
atum (Fig. 6E). The CMA receptor LAMP-2A remained unchanged in the
substantia nigra and striatum following a co-injection of AAV-mutant
A53T α-synuclein and AAV-GBA1 (Fig. 6C,F).
4. Discussion
Mutations in GBA1 are frequently observed in sporadic PD patients.
These mutations are associated with a reduction in GCase activity and
an increase in Lewy body inclusions (Neumann et al., 2009; Sidransky
et al., 2009). Genetic studies have also implicated other lysosomal-
associated genes with sporadic PD. A loss-of-function mutation in the
lysosomal cation-transporting ATPase, Adenosine-3-phosphate 13A2
(ATP13A2) will result in abnormal lysosomal acidiﬁcation in Kufor–
Rakeb syndrome as well as some juvenile and young-onset forms of
PD (Di Fonzo et al., 2007; Park et al., 2011; Ramirez et al., 2006). Muta-
tions in the lysosomal proton transporting ATPase, ATP6AP2 causes X-
linked parkinsonism with spasticity (Korvatska et al., 2013), and a
mutation in VPS35, an endosomal–lysosomal trafﬁcking gene, causes
autosomal dominant forms of PD (Vilarino-Guell et al., 2011; Zimprich
et al., 2011). More recently, a loss-of-function mutation in SMPD1
(p.L302P), a gene linked with Niemann–Pick diseases Type A and Type
B, and which leads to an accumulation of sphingomyelin, has been
shown to be strongly associated with PD (Gan-Or et al., 2013), and the
presence of phosphorylated α-synuclein and Lewy bodies has been de-
scribed in the brains of patients with Niemann–Pick disease Type C1
(Chiba et al., 2014; Saito et al., 2004). In the future, it will be interesting
to identify the molecular links between SMPD1, in particular the
p.L302Pmutation, andα-synucleinopathy. Collectively, these lysosomal
genemutations suggest that impairments in lysosomal degradation sys-
tems are implicated in the disease process and may even be causative
for PD.
This report demonstrates that overexpression of GBA1 is neuropro-
tective and can modulate α-synuclein accumulation using two rodent
models of PD. First, we demonstrate that overexpression of GBA1 in-
creases levels of LC3-II and prevents accumulation of insoluble α-
synuclein in a transgenic mouse model of α-synucleinopathy. Second,
using a ratmodel of selectivemidbrain dopamine neuron degeneration,
we show for the ﬁrst time that overexpression of GBA1 protects against
mutant A53Tα-synuclein induced neurodegeneration. In support of our
data, AAV-mediated overexpression of GBA1 has also been shown to
prevent both α-synuclein and Tau pathology in the hippocampus in a
mouse model of Gaucher's disease and modestly diminish Tris soluble
α-synuclein in the striatum of A53T α-synuclein transgenic mice
(Sardi et al., 2011; Sardi et al., 2013). Collectively, these data suggest
that increasing GCase activity may have therapeutic potential to treat
PD.
5. Overexpression of GCase protected dopaminergic neurons in
the substantia nigra against mutant A53T α-synuclein induced
neurodegeneration
We have previously demonstrated that an intra-nigral injection of
AAV-A53T α-synuclein induces a progressive retrograde degeneration
of nigrostriatal dopamine neurons over a 6-month period, which is
preceded by the development of dystrophic dopamine axons in the stri-
atum as early as 4–8 weeks after AAV injection (Chung et al., 2009).
Using this model, our current data show that mutant A53T α-
synuclein overexpression was associated with diminished levels of
LC3-II (a marker of autophagosomes) in the striatum but not in the
substantia nigra at 8 weeks after AAV injection, possibly indicating a
lower number of available autophagosomes for lysosomal degradation
at striatal terminals. Reduced LC3-II levels in the striatum but not in
the substantia nigra may reﬂect the retrograde pattern of degeneration
characteristic of this α-synucleinopathy model. The reduction of LC3-II
Fig. 3. Intra-cerebral injection of AAV-GBA1 reduced insoluble α-synuclein aggregates in ASO mice, 8-months post-gene therapy delivery. Two- to three-month old ASO mice received
unilateral injections of either AAV-GFP (control) or AAV-GBA1 transgene into the substantia nigra and striatum. At 8-months post-gene delivery, transgene expression of AAV-GFP and
AAV-GBA1was veriﬁed in the substantia nigra (A) and striatum (C). The number of insolubleα-synuclein aggregates (illustrated using white arrows) in the substantia nigra (B) and stri-
atum (D) of ASOmice was decreased following AAV-GBA1 gene delivery in comparison to AAV-GFP control ASO mice. Scale bar = 25 μm. N=4–6 animals per group. Data are analyzed
using an unpaired two-tailed T-test test, *p b 0.05, graphs are expressed as mean ± SEM.
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AAV-A53Tα-synuclein. Our data did not show alterations in the protein
expression of LAMP-2A,which is required for CMA, followingAAV-A53T
α-synuclein overexpression. There are several reports linking α-
synuclein turnover with LAMP-2A and CMA (reviewed in Xilouri and
Stefanis (2015)) and further in-depth studies that examine multiple
time points during the degenerative period in the AAV-A53T α-
synuclein model, as well as the use of lysosomal enriched fractions,
may reveal further insights into LAMP-2A-mediated mechanisms.
Importantly, at 6 months after AAV injection, GBA1 overexpression
protected against mutant A53T α-synuclein-induced degeneration of
dopaminergic cell bodies. This is the ﬁrst evidence to our knowledge
demonstrating that increased GCase can prevent dopamine neuron
loss in a rodent model of α-synucleinopathy. Intra-nigral injection of
AAV-GBA1 was associated with increased GCase activity, and overex-
pression of GCase in dopaminergic neurons was maintained even up
to 6-months post-gene delivery. Future studies will determine the pro-
portion of GCase localized in lysosomes in this GBA1 overexpression
paradigm—although it is possible that excess GCase may accumulatein the ER and disrupt trafﬁcking of GCase from the ER to the lysosome,
it is unlikely that in such a scenario the protective effect of AAV-GBA1
against α-synucleinopathy-induced dopamine neuron degeneration
would have been observed.
The hypothesized link between GCase and lysosomal function sug-
gested by our current ﬁndings, is supported by recent data showing
that a loss of GCase activity early in sporadic PD corresponds to reduced
protein levels of beclin-1 (regulator of autophagy), LAMP-2A (CMA re-
ceptor), and increased oligomeric α-synuclein levels (Murphy et al.,
2014). Therefore, up-regulation of speciﬁc genes in the autophagy–lyso-
somal degradation pathway early in the disease process may delay or
even prevent the progression of PD.
6. Overexpression of GCase enhanced lysosomal activity and
improved α-synuclein clearance in mice overexpressing human
wildtype α-synuclein
Using a mouse model of α-synucleinopathy, which causes wide-
spreadα-synuclein inclusions in the absence of overt neurodegeneration,
Fig. 4. Intra-nigral administration of AAV-GBA1 causes an increase in GCase protein levels and activity. Naive rats received an intra-nigral injection of AAV-GFP control transgene or a co-
injection of either AAV-GFP + AAV-mutant A53T α-synuclein or AAV-GBA1 + AAV-mutant A53T α-synuclein (A). At 8-weeks post-AAV injection, this resulted in an increase in GCase
activity in the substantia nigra (B, C). N= 5 animals per group. At 24-weeks post-AAV injection, the expression of transgenes in the substantia nigra dopamine neurons was conﬁrmed
using immunoﬂuorescence (D) labeling for GFP, humanα-synuclein and TH and GBA1, humanα-synuclein and TH.N=4–10 animals per group.Western blots show two representative
samples from each group. Data are analyzed using a 1-way ANOVA followed by Bonferonni post-hoc test, *p b 0.05, graphs are expressed as mean ± SEM.
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clusions in the substantia nigra and striatumandnot in the hippocampus.
GBA1 overexpression has previously been shown to reduce levels of sol-
uble α-synuclein in the striatum in a different mouse model of α-Fig. 5. Intra-nigral administration of AAV-GBA1 is neuroprotective against the A53Tα-synuclein
and subsequent stereological analysis of the total number of dopamine neurons (TH/NeuN cola
tration of AAV-mutant A53T α-synuclein caused ~50% decrease in the dopamine neurons com
GBA1 rescued dopamine neurons from the mutant A53T α-synuclein induced degeneration (
by Bonferonni post-hoc test, *p b 0.05, graphs are expressed as mean ± SEM.synucleinopathy that overexpresses mutant A53T α-synuclein (Sardi
et al., 2013). However, to our knowledge, ours is the ﬁrst report demon-
strating that GBA1 gene therapy can initiate the clearance of insolubleα-
synuclein aggregateswithin the substantia nigra. In the current study, theinduced neurodegeneration. Immunolabeling for TH (brown) and NeuN (black) (A, B, C),
beled cells) in the substantia nigra pars compacta, indicated that an intra-nigral adminis-
pared to control rats injected with AAV-GFP (A, B, D). Intra-nigral administration of AAV-
B, C, D). N= 4–10 animals per group. Data are analyzed using a 1-way ANOVA followed
Fig. 6.Mutant A53Tα-synuclein induces alterations in the levels of proteins involved in the autophagy pathway, which are prevented by an intra-nigral injection of AAV-GBA1. Western
blots were performed using total lysate (10–20 μg) of naive rats that received an intra-nigral injection of AAV-GFP control transgene or a co-injection of either AAV-GFP + AAV-mutant
A53T α-synuclein or AAV-GBA1 + AAV-mutant A53T α-synuclein. At 8-weeks post-AAV-mutant A53T α-synuclein, the lipidated form of LC3 (LC3-II) remained unchanged in the
substantia nigra (A) and decreased in the striatum of rats injectedwith mutant A53Tα-synuclein (D), whichwere restored by AAV-GBA1. Levels of p62 were decreased in the substantia
nigra of rats that received AAV-mutant A53T α-synuclein and restored when co-administered with AAV-GBA1 (B). Levels of p62 were increased in the striatum of rats that also were co-
administered AAV-mutant A53T α-synuclein and AAV-GBA1(E). LAMP-2A remained unchanged in the substantia nigra and striatum (C and F). N= 4–5 animals per group. Data are
analyzed using a 1-way ANOVA followed by Bonferonni post-hoc test, *p b 0.05, graphs expressed as mean ± SEM. Western blots show two representative samples from each group.
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striatum of ASOmice treatedwith AAV-GBA1 coincidedwith an increase
in levels of LC3-II protein. Despite an increase in GCase activity in the hip-
pocampus, levels of LC3-II were not elevated in this region. The observed
increase in LC3-II in the substantia nigra and striatum through overex-
pression of GBA1 could indicate either an induction of macroautophagy
or defective clearance of autophagosomes. Further experiments will be
required to elucidate the role of LC3-II in the AAV-GBA1-mediated reduc-
tion ofα-synucleinopathy. Overall, our data showing a therapeutic effect
ofGBA1 gene therapy onα-synucleinopathy are not surprising given that
reduced levels of GCase results in the accumulation of oligomeric and ag-
gregated forms of α-synuclein (Mazzulli et al., 2011; Osellame et al.,
2013; Rocha et al., 2015b; Sardi et al., 2011; Sardi et al., 2013). Further-
more, a recent study demonstrates that systemic exposure to a GCase
pharmacological chaperone in ASO mice diminishes behavioral deﬁcits,
reduces substantia nigra α-synuclein aggregates, and decreases α-
synuclein immunoreactivity within dopamine neurons (Richter et al.,
2014).
In addition to these data, in vivo and in vitro models of PD further
support the role of dysfunctional autophagy–lysosomal degradation
pathways in PD. The autophagy-related protein Atg7 is required forthe conversion of LC3-I to its lipidated form LC3-II, and conditional
knockdown of atg7 results in age-dependent neuropathological and
motor deﬁcits reminiscent of PD, including loss of dopaminergic
neurons, accumulation of α-synuclein, and the accumulation of
ubiquitinated protein aggregates (Ahmed et al., 2012). Moreover,
overexpression of beclin-1 causes an increase in LC3-II, which is
accompanied by a reduction of cortical α-synuclein levels (Spencer
et al., 2009), and overexpression of TFEB (master regulator of au-
tophagy–lysosomal pathways) up-regulates many autophagy-
related proteins and prevents the loss of nigral DA neurons caused
by accumulation of toxic α-synuclein oligomers (Decressac et al.,
2013). Lastly, GBA1-PD patient derived DA neurons are associated
with defects in autophagic–lysosomal degradation pathways, in-
cluding dysregulated LC3-II levels, reduced lysosomal GCase levels
and elevated α-synuclein. These pathological changes are not
found in corresponding gene corrected iPSC-derived DA neurons
(Schondorf et al., 2014). Further studies will examine in more detail
how lysosomal function is affected in the α-synucleinopathy models
used in the current study, including markers of lysosomal activity
and autophagic ﬂux, and determinewhich aspects of lysosomal func-
tion are altered by GBA overexpression.
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ually decline with aging (Martinez-Vicente et al., 2005; Rocha et al.,
2015a). Moreover, there is an age-dependent reduction in GCase activ-
ity in healthy subjects in the brain regions most affected in PD (Rocha
et al., 2015a). It is unclear if this age-dependent reduction in GCase
activity is pathological by contributing to age-related lysosomal impair-
ments that result in deﬁcits in autophagy degradation pathways. The
only known regulator of GCase expression is the TFEB, which regulates
lysosomal biogenesis, and lysosomal clearance of organelles, lipids and
proteins (Settembre et al., 2011). Histological examination of postmor-
tem PD midbrains reveals a signiﬁcant reduction of nuclear TFEB ex-
pression, and accumulation of cytoplasmic TFEB colocalizes with α-
synuclein in Lewy body containing nigral neurons (Decressac et al.,
2013). Several other autophagy–lysosomal related proteins, including
ATP13A2 and LAMP-2A, are downregulated in dopaminergic neurons
of sporadic PD patients (Decressac et al., 2013; Dehay et al., 2012;
Gegg et al., 2012; Murphy et al., 2014). Disruption in autophagy–lyso-
somal protein levels during the early stages of PD will likely alter lyso-
somal membrane properties and impair proper protein degradation,
thus exacerbating any age-related lysosomal dysfunction. Diminished
GCase activity levels have been reported in the amygdala, striatum
and substantia nigra of non-GBA1 PD patients (Gegg et al., 2012;
Rocha et al., 2015a). This reduction in GCase activity is associated with
an accumulation of GluSph, high levels of α-synuclein and alterations
in LAMP-2A early during the disease progression (Murphy et al., 2014;
Rocha et al., 2015a).
In summary, using twomodels ofα-synucleinopathy, we have dem-
onstrated that GBA gene delivery to the substantia nigra and striatum
can facilitate the clearance of insolubleα-synuclein aggregates and pro-
tect against mutant A53T α-synuclein induced neurodegeneration.
These data validate lysosomal genes as new potential targets to reduce
levels of misfolded α-synuclein in PD.
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